FSFI desire score is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
== Career and research == Tschöp obtained an M.D. from LMU Munich (1993), where he worked as a clinician (1994–1998) in neuroendocrinology before accepting a research fellowship at the Eli Lilly Discovery Research Laboratories (1999–2002) and leading a research team at the German Institute of Human Nutrition (Potsdam/Nuthetal 2002–2003). He was a Professor of Endocrinology and Diabetes at the Metabolic Diseases Institute of the University of Cincinnati (2003–2009), before being named the Arthur Russell Morgan Endowed Chair of Medicine, and Research Director of the Metabolism Center of Excellence for Diabetes and Obesity at the University of Cincinnati (2009–2011). He was Research Director of the Helmholtz Diabetes Center and Director of the Institute for Diabetes and Obesity at Helmholtz Zentrum München (2011–2018). Early in his career, Tschöp reported on the orexigenic, adipogenic, and metabolic effects of ghrelin and its secretory control by nutrients, which has had a major influence on human obesity and diabetes research. His corresponding publication in Nature is among today's most frequently cited metabolism research papers. It added a fundamental pathway to the current model of body weight and glucose control and established novel drug targets for metabolic diseases. Tschöp went on to further dissect gut-brain communication pathways, based on GI-hormone signaling and lessons from unraveling the molecular underpinnings of gastric bypass surgery.
== Use in synthesis reactions == D-amino acid dehydrogenase has shown itself to be effective in the synthesis of branched-chain amino acids such as D-leucine, D-isoleucine, and D-valine. In the given study, researchers were successfully able to use D-amino acid dehydrogenase to create high amounts of these products from the starting material of 2-oxo acids, in the presence of ammonia. The conditions for this were variable, though the best results appeared at around 65 °C. Amino Acids obtained through these reactions resulted in a high enantioselectivity of >99% and high yields of >99%. Given the nature of this enzyme, it may be possible to use it in order to create non-branched D-amino acids as well as modified D-amino acids.
== Exceptions == Genetics does not determine the language spoken by a human being, and the link between Y-chromosomal haplogroups and linguistic affinities is an observed correlation and not a causal link. While father tongues predominate, exceptions to father tongues exist in the world. One possible exception is the Balti in northern Pakistan. The mtDNA haplogroups most frequent among Balti are the same as those of the neighbouring Tibetan communities, whereas the Y-chromosomal haplogroups most frequent in Balti males appear to have entered Baltistan from the west with the introduction of Islam. The Balti speak one of the most conservative Tibetan languages. The language of the Balti corresponds to the mtDNA and not to the Y chromosome and is in effect a salient example of a mother tongue.
genetic recombination Any reassortment or exchange of genetic material within an individual organism or between individuals of the same or different species, especially that which creates genetic variation. In the broadest sense, the term encompasses a diverse class of naturally occurring mechanisms by which nucleic acid sequences are copied or physically transferred into different genetic environments, including homologous recombination during meiosis or mitosis or as a normal part of DNA repair; horizontal gene transfer events such as bacterial conjugation, viral transduction, or transformation; or errors in DNA replication or cell division. Artificial recombination is central to many genetic engineering techniques which produce recombinant DNA.
Although a given protein sequence may contain domains found in several superfamilies, thus indicating a complex evolutionary history, sequences will be assigned to only one homeomorphic superfamily based on the presence of similarity throughout a multiple sequence alignment. The superfamily alignment may also include regions that do not align either within or at the ends of the alignment. In contrast, sequences in the same family align well throughout the alignment. Supersecondary structure a term with similar meaning to a structural motif. Tertiary structure is the three-dimensional or globular structure formed by the packing together or folding of secondary structures of a polypeptide chain.
Sources: en.wikipedia.org
In a solid, shear stress is a function of strain, but in a fluid, shear stress is a function of strain rate. A consequence of this behavior is Pascal's law which describes the role of pressure in characterizing a fluid's state. The behavior of fluids can be described by the Navier–Stokes equations—a set of partial differential equations which are based on:
Absence of antibodies in patients with diagnoses of an autoimmune thyroid in their past would always be suspicious for development to SAT even in the presence of a normal TSH because there is no known recovery from autoimmunity. For clinical interpretation of laboratory results it is important to acknowledge that TSH is released in a pulsatile manner resulting in both circadian and ultradian rhythms of its serum concentrations.
In 2012, newly elected President Enrique Peña Nieto, from the PRI, emphasized that he did not support the involvement of armed American agents in Mexico and was only interested in training Mexican forces in counter-insurgency tactics. At the start of his term, Peña Nieto promised to de-escalate the conflict, focusing on lowering criminal violence rates, as opposed to the previous policy of attacking drug-trafficking organizations by arresting or killing the cartel leaders and intercepting their shipments. His administration's security policy was shaped by Miguel Ángel Osorio Chong (Secretary of the Interior), Jesús Murillo Karam (Attorney General), and Salvador Cienfuegos (National Defense). In the first 14 months of his administration, between December 2012 and January 2014, 23,640 people died in the conflict. During 2012 and 2013, Mexico saw the rise of grupos de autodefensa comunitaria, vigilante self-defense groups in rural communities that took up arms against criminal groups that wanted to impose dominance in their towns, entering a new phase in the Mexican drug war. This strategy, encouraged by Óscar Naranjo, one of Peña Nieto's security advisors, crumbled when autodefensas began having internal struggles and disagreements with the government, as well as infiltration and co-optation by organized crime, causing Peña Nieto's administration to distance from them.
Moroidin and its analogous celogentins all have activity comparable to that of vinblastine, and a third group of celogentins all have reduced activity. In contrast, stephanotic acid, a cyclic compound analogous only to the left-hand ring and containing the same Leu-His linkage, has no anti-mitotic activity. Other anti-tubulin agents used as chemotherapy agents have painful side effects known as neuropathy when the drugs are exposed to tissue. Although the exact mechanism for the cause of neuropathy is unknown, it is thought to be related to the degradation of microtubules, which are essential components of neurons.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.